FDA-2024-0081-V381

Type IA variation for application FDA-2024-0081. Type IA variation: Formulation Change for Lorlatenilib — routine update

Variation Number
FDA-2024-0081-V381
Type
Type IA
Application
FDA-2024-0081
Change
CHG-2024-0081
Status
Overdue
Fee
€898
Submitted
—
Approved
—
Description

Type IA variation: Formulation Change for Lorlatenilib — routine update